公开(公告)号：US20240350623A1

公开(公告)日：2024-10-24

申请号：US18444286

申请日：2024-02-16

Applicant: Zivo Bioscience, Inc.

Inventor： Amy E. Steffek ,  Andrew A. Dahl ,  William P. Pfund

IPC: A61K39/39 ,  A23K10/16 ,  A23K20/163 ,  A23K50/75 ,  A61K31/739 ,  A61K35/74 ,  A61K39/00 ,  A61K39/02 ,  A61P33/02

CPC classification number: A61K39/39 ,  A23K10/16 ,  A23K20/163 ,  A23K50/75 ,  A61K31/739 ,  A61K35/74 ,  A61K39/0208 ,  A61P33/02 ,  A61K2039/552 ,  A61K2039/55572

Abstract: A method and compound for altering the status of both innate and adaptive immune pathways in both animals and humans are disclosed. The status alteration results in the immune response being primed whereby an accelerated and more robust response is generated when the animal or human is challenged by pathogens that lead to a wide range of disease states. The disclosed method utilizes a compound derived from a lipopolysaccharide (LPS) of gram-negative bacteria. The compound itself is a natural product with no observed adverse environmental impact. By priming the immune pathways according to the disclosed inventive concept, the severity of various disease states can be reduced, can be resolved more quickly, or can be avoided entirely.

公开(公告)号：US20240009291A1

公开(公告)日：2024-01-11

申请号：US18350526

申请日：2023-07-11

Applicant: Arkea Bio Corp.

Inventor： Colin South ,  Matthew Dunn ,  Lauren Fitch ,  Joseph Koos ,  Laura Holland ,  Brigid Arciero ,  James Spoonamore ,  Caitlin Allen ,  Alexander Hsu ,  Sara Tabandeh ,  Frederick Richard Kearney

IPC: A61K39/02 ,  A61K9/50 ,  A61K9/24 ,  A61K9/28 ,  A61K9/20 ,  A61P31/04

CPC classification number: A61K39/0208 ,  A61K9/5052 ,  A61K9/209 ,  A61K9/2866 ,  A61K9/205 ,  A61K9/2054 ,  A61K9/2063 ,  A61K9/2009 ,  A61P31/04 ,  A61K2039/552

Abstract: The present invention is related to compositions and methods that reduce methane production in ruminant populations.

公开(公告)号：US20230235030A1

公开(公告)日：2023-07-27

申请号：US18168824

申请日：2023-02-14

Applicant: Research Institute at Nationwide Children's Hospital

Inventor： Steven D. Goodman ,  Lauren O. Bakaletz

IPC: C07K16/12 ,  A01N37/46 ,  A61K39/02 ,  A61K39/395 ,  A61K39/40 ,  A61K45/06 ,  C07K16/40 ,  G01N33/569 ,  G01N33/68

CPC classification number: C07K16/1242 ,  A01N37/46 ,  A61K39/0208 ,  A61K39/39541 ,  A61K39/40 ,  A61K45/06 ,  C07K16/12 ,  C07K16/1232 ,  C07K16/40 ,  G01N33/56911 ,  G01N33/6854 ,  G01N33/6893 ,  G01N2800/24 ,  A61K2039/505

Abstract: This disclosure provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that cannot form functional biofilms are more readily cleared by the remainder of the host's immune system and/or traditional antibiotics.

公开(公告)号：US20230212633A1

公开(公告)日：2023-07-06

申请号：US18068435

申请日：2022-12-19

Applicant: Northwestern University ,  Cornell University

Inventor： Michael Christopher Jewett ,  Jessica Carol Stark ,  Matthew P. DeLisa ,  Thapakorn Jaroentomeechai

IPC: C12P21/00 ,  A61K39/39 ,  A61K39/02 ,  A61K39/108

CPC classification number: C12P21/005 ,  A61K39/39 ,  A61K39/0208 ,  A61K39/0258 ,  A61K2039/6037

Abstract: Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated carrier proteins. The glycosylated carrier proteins may be utilized in vaccines, including anti-bacterial vaccines. The glycosylated carrier proteins may include a bacterial polysaccharide conjugated to a carrier, which may be utilized to generate an immune response in an immunized host against the polysaccharide conjugated to the carrier. The glycosylated carrier proteins may be synthesized in cell-free glycoprotein synthesis (CFGpS) systems using prokaryote cell lysates that are enriched in components for glycoprotein synthesis such as oligosaccharyltransferases (OSTs) and lipid-linked oligosaccharides (LLOs) including OSTs and LLOs associated with synthesis of bacterial O antigens.

公开(公告)号：US11692229B2

公开(公告)日：2023-07-04

申请号：US17033034

申请日：2020-09-25

Applicant: The Regents of the University of California

Inventor： Huiying Li ,  Shuta Tomida ,  Robert L. Modlin ,  Jeffery F. Miller ,  Sorel T. Fitz-Gibbon

IPC: C12Q1/689 ,  C12Q1/6883 ,  A61K39/05 ,  A61K35/741 ,  A61K35/76 ,  A61K39/02 ,  C12N7/00 ,  C12Q1/70

CPC classification number: C12Q1/689 ,  A61K35/741 ,  A61K35/76 ,  A61K39/0208 ,  A61K39/05 ,  C12N7/00 ,  C12Q1/6883 ,  C12Q1/701 ,  C12N2795/00032 ,  C12Q2600/112 ,  C12Q2600/156 ,  C12Q2600/16

Abstract: Methods of diagnosing and treating patients afflicted with acne, including diagnosing one as having acne if the individual possesses RT4, RT5, RT7, RT8, RT9, or RT10. Methods for treating acne include administering an effective amount of a drug specifically targeting RT4, RT5, RT7, RT8, RT9, or RT10, such as small molecules, antisense molecules, siRNAs, biologics, antibodies, phages, vaccines, or combination thereof.

公开(公告)号：US20230190829A1

公开(公告)日：2023-06-22

申请号：US18050091

申请日：2022-10-27

Applicant: KoBioLabs, Inc.

Inventor： Gwangpyo KO ,  Boram SEO ,  Woon Ki KIM ,  Kyungchan JEON

IPC: A61K35/741 ,  A23L33/135 ,  A61K39/02

CPC classification number: A61K35/741 ,  A23L33/135 ,  A61K39/0208 ,  A61K2035/115

Abstract: The present invention relates to a microorganism which can act as a biomarker of alcoholic fatty liver disease, and relates to a pharmaceutical composition for preventing or treating alcoholic fatty liver disease, a food composition for preventing or improving alcoholic fatty liver disease, or a probiotics composition for preventing or improving alcoholic fatty liver disease, comprising the strain as an active ingredient.

公开(公告)号：US20180333476A1

公开(公告)日：2018-11-22

申请号：US15918117

申请日：2018-03-12

Applicant: Baylor College of Medicine

Inventor： Leonard WEISMAN ,  Lingkun KONG

IPC: A61K39/02 ,  C07K16/12 ,  G01N33/569 ,  A61K39/00

CPC classification number: A61K39/0208 ,  A61K39/02 ,  A61K39/0241 ,  A61K2039/53 ,  C07K16/1253 ,  G01N33/56911 ,  G01N2333/30 ,  G01N2469/10

Abstract: The present invention encompasses methods and compositions for Ureaplasma infection prevention and/or treatment. In specific cases, the invention concerns vaccines for Ureaplasma, including DNA vaccines. In certain embodiments, the invention regards vaccines directed towards the multiple-banded antigen(s) of Ureaplasma.

公开(公告)号：US10046038B2

公开(公告)日：2018-08-14

申请号：US14650720

申请日：2013-12-20

Applicant: Intervet Inc.

Inventor： Christian Theodoor Gerardus Smits ,  Edwin Kets ,  Henriette Adriaanse

IPC: A61K39/02 ,  C12N1/20 ,  C12R1/01 ,  C12N1/38 ,  A61K39/00

CPC classification number: A61K39/0208 ,  A61K39/0225 ,  A61K2039/521 ,  C12N1/20 ,  C12N1/38 ,  C12R1/01 ,  Y02A50/48

Abstract: The antigenic mass of Leptospira cultures can be significantly increased, independent from any increase in biomass, by supplementing Leptospira cultures with a specific type of fatty acid: a polyunsaturated C18 fatty acid. This provides advantages in the production Leptospira antigens. Also this enables the production of improved Leptospirosis vaccines, that are safer and more effective.

公开(公告)号：US20180071384A1

公开(公告)日：2018-03-15

申请号：US15560462

申请日：2016-03-24

Applicant: IQUR LIMITED

Inventor： Michael Anthony Whelan ,  Robert A. Field ,  David J. Rowlands

IPC: A61K39/29 ,  A61K39/02 ,  A61K39/385 ,  C07K14/02 ,  C12N7/00

CPC classification number: A61K39/292 ,  A61K39/0208 ,  A61K39/385 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/6075 ,  A61K2039/64 ,  A61K2039/70 ,  C07K14/005 ,  C07K14/02 ,  C12N7/00 ,  C12N2730/10122 ,  C12N2730/10123 ,  C12N2730/10134 ,  C12N2730/10151 ,  C12N2730/10171

Abstract: The invention provides a protein comprising hepatitis B core antigen (HBcAg) with a sequence of the formula XpZqXr in an e1 loop, wherein X is a negatively charged amino acid residue, Z is a positively charged amino acid residue, and p, q N and r are each independently an integer from 1 to 12, and wherein a sugar is attached to a Z residue. The protein may comprise a first and a second copy of HBcAg in tandem, wherein one or both copies of HBcAg has a sugar attached to the e1 loop. The first copy may have a sugar attached to the e1 loop and the second copy may comprise a peptide epitope in the e1 loop. The protein may be used to induce an immune response against the sugar and hence act as a vaccine.

公开(公告)号：US09913888B2

公开(公告)日：2018-03-13

申请号：US15036229

申请日：2014-11-13

Applicant: NORGES MILJØ-OG BIOVITENSKAPELIGE UNIVERSITET (NMBU)

Inventor： Henning Sørum

IPC: A61K39/02 ,  A61K39/00 ,  A23K10/16 ,  A23K10/18 ,  A23K50/80 ,  C12N1/20 ,  C12R1/01

CPC classification number: A61K39/0216 ,  A23K10/16 ,  A23K10/18 ,  A23K50/80 ,  A61K39/0208 ,  A61K39/105 ,  A61K2039/521 ,  A61K2039/522 ,  A61K2039/54 ,  A61K2039/552 ,  A61K2039/70 ,  C12N1/20 ,  C12R1/01

Abstract: The present document discloses a new species of Bizionia, herein denoted Bizionia piscinecroseptica and a reference strain of this bacterium denoted Bizionia sp. 130524K2F7 which has been deposited at the National Collection of Industrial and Marine Bacteria and has been assigned accession number NCIMB 42183. Further disclosed is the medical use of bacteria of the genus Bizionia for vaccinating fish against a new disease identified and herein denoted bizioniosis.